tetano
Editor, Senior Moderator
Clin Exp Nephrol
. 2024 Mar 8.
doi: 10.1007/s10157-024-02477-8. Online ahead of print. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients
Ayumi Yoshifuji[SUP] #[/SUP][SUP] 1 2 [/SUP], Masataro Toda[SUP] #[/SUP][SUP] 3 [/SUP], Emi Oyama[SUP] 3 [/SUP], Tetsuo Nakayama[SUP] 4 [/SUP], Setsuko Mise-Omata[SUP] 5 [/SUP], Kan Kikuchi[SUP] 6 [/SUP], Mamoru Yoshizawa[SUP] 7 [/SUP], Naohiko Kato[SUP] 8 [/SUP], Haruki Wakai[SUP] 9 [/SUP], Kiyoto Koibuchi[SUP] 10 [/SUP], Kohkichi Morimoto[SUP] 11 [/SUP], Yoshifumi Uwamino[SUP] 12 13 [/SUP], Ho Namkoong[SUP] 12 [/SUP], Ayako Shibata[SUP] 13 [/SUP], Kaoru Wakabayashi[SUP] 14 [/SUP], Motoko Fujino[SUP] 15 [/SUP], Motoaki Komatsu[SUP] 3 [/SUP], Naoki Mochizuki[SUP] 16 [/SUP], Norihiko Kondo[SUP] 17 [/SUP], Akihiko Yoshimura[SUP] 5 [/SUP], Naoki Hasegawa[SUP] 12 [/SUP], Munekazu Ryuzaki[SUP] 18 [/SUP]
Affiliations
Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.
Methods: Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.
Results: Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.
Conclusions: HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.
Keywords: BNT162b2 vaccine; Booster vaccine; COVID-19; Hemodialysis; Hypoimmunity; Peritoneal dialysis.
. 2024 Mar 8.
doi: 10.1007/s10157-024-02477-8. Online ahead of print. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients
Ayumi Yoshifuji[SUP] #[/SUP][SUP] 1 2 [/SUP], Masataro Toda[SUP] #[/SUP][SUP] 3 [/SUP], Emi Oyama[SUP] 3 [/SUP], Tetsuo Nakayama[SUP] 4 [/SUP], Setsuko Mise-Omata[SUP] 5 [/SUP], Kan Kikuchi[SUP] 6 [/SUP], Mamoru Yoshizawa[SUP] 7 [/SUP], Naohiko Kato[SUP] 8 [/SUP], Haruki Wakai[SUP] 9 [/SUP], Kiyoto Koibuchi[SUP] 10 [/SUP], Kohkichi Morimoto[SUP] 11 [/SUP], Yoshifumi Uwamino[SUP] 12 13 [/SUP], Ho Namkoong[SUP] 12 [/SUP], Ayako Shibata[SUP] 13 [/SUP], Kaoru Wakabayashi[SUP] 14 [/SUP], Motoko Fujino[SUP] 15 [/SUP], Motoaki Komatsu[SUP] 3 [/SUP], Naoki Mochizuki[SUP] 16 [/SUP], Norihiko Kondo[SUP] 17 [/SUP], Akihiko Yoshimura[SUP] 5 [/SUP], Naoki Hasegawa[SUP] 12 [/SUP], Munekazu Ryuzaki[SUP] 18 [/SUP]
Affiliations
- PMID: 38457030
- DOI: 10.1007/s10157-024-02477-8
Background: Dialysis patients are susceptible to developing severe coronavirus disease 2019 (COVID-19) due to hypoimmunity. Antibody titers against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) after the primary vaccinations are lower in hemodialysis (HD) patients than in healthy individuals. This study aimed to evaluate the effect of a SARS-CoV-2 booster vaccination in HD and peritoneal dialysis (PD) patients based on antibody titers and cellular and humoral immunity.
Methods: Participants of the control, HD, and PD groups were recruited from 12 facilities. SARS-CoV-2 antigen-specific cytokine and IgG-antibody levels were measured. Regulatory T cells and memory B cells were counted using flow cytometry at 6 months after primary vaccination with BNT162b2 and 3 weeks after the booster vaccination in HD and PD patients and compared with those of a control group.
Results: Booster vaccination significantly enhanced the levels of antibodies, cytokines, and memory B cells in three groups. The HD group showed significantly higher levels of IgG-antibodies, IL-1β, IL-2, IL-4, IL-17, and memory B cells than those in the control group at 3 weeks after the booster dose. The PD group tended to show similar trends to HD patients but had similar levels of IgG-antibodies, cytokines, and memory B cells to the control group.
Conclusions: HD patients had significantly stronger cellular and humoral immune responses than the control 3 weeks after the booster dose. Our findings will help in developing better COVID-19 vaccination strategies for HD and PD patients.
Keywords: BNT162b2 vaccine; Booster vaccine; COVID-19; Hemodialysis; Hypoimmunity; Peritoneal dialysis.